Supplement 4 from Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
We conducted a phase II multicenter single arm trial of pembrolizumab and cabozantininb in patients with Recurrent Metastatic Head and Neck Squamous Cell Carcinoma). We extracted DNA from 16 tumors an
In recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC) not amenable to salvage surgery or radiation, the overall survival remains unsatisfactory, and the patients often experience a h
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab
Introduction: Immune-checkpoint inhibition has improved the outcomes of patients with a metastatic squamous cell carcinoma in the head and neck. The combination of pembrolizumab, platinum agent, and 5
